TELA Bio Files 8-K on Financials and Operations
Ticker: TELA · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1561921
| Field | Detail |
|---|---|
| Company | Tela Bio, Inc. (TELA) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations
TL;DR
TELA Bio dropped an 8-K detailing financial results and operations. Check it out.
AI Summary
TELA Bio, Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition. The filing also includes disclosures related to Regulation FD and financial statements/exhibits. The company is incorporated in Delaware and headquartered in Malvern, Pennsylvania.
Why It Matters
This 8-K filing provides investors with crucial updates on TELA Bio's financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting financial and operational information, not indicating any immediate or unusual risks.
Key Players & Entities
- TELA Bio, Inc. (company) — Registrant
- August 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Malvern, Pennsylvania (location) — Principal executive offices
- 484-320-2930 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are being reported in this 8-K?
This 8-K filing indicates that it reports on 'Results of Operations and Financial Condition' but does not provide specific financial figures within the provided text.
When was this 8-K filed?
This 8-K was filed on August 12, 2024.
What is the principal business address of TELA Bio, Inc.?
The principal executive offices are located at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355.
What is TELA Bio, Inc.'s Commission File Number?
TELA Bio, Inc.'s Commission File Number is 001-39130.
What other information is included in this 8-K filing besides financial results?
This filing also includes disclosures related to Regulation FD and Financial Statements and Exhibits.
Filing Stats: 651 words · 3 min read · ~2 pages · Grade level 9.9 · Accepted 2024-08-12 16:15:39
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market
Filing Documents
- tm2421368d1_8k.htm (8-K) — 30KB
- tm2421368d1_ex99-1.htm (EX-99.1) — 99KB
- tm2421368d1_ex99-2.htm (EX-99.2) — 32KB
- tm2421368d1_ex99-1img001.jpg (GRAPHIC) — 22KB
- tm2421368d1_ex99-2img001.jpg (GRAPHIC) — 96KB
- tm2421368d1_ex99-2img002.jpg (GRAPHIC) — 220KB
- tm2421368d1_ex99-2img003.jpg (GRAPHIC) — 105KB
- tm2421368d1_ex99-2img004.jpg (GRAPHIC) — 114KB
- tm2421368d1_ex99-2img005.jpg (GRAPHIC) — 80KB
- tm2421368d1_ex99-2img006.jpg (GRAPHIC) — 129KB
- tm2421368d1_ex99-2img007.jpg (GRAPHIC) — 67KB
- tm2421368d1_ex99-2img008.jpg (GRAPHIC) — 130KB
- tm2421368d1_ex99-2img009.jpg (GRAPHIC) — 122KB
- tm2421368d1_ex99-2img010.jpg (GRAPHIC) — 125KB
- tm2421368d1_ex99-2img011.jpg (GRAPHIC) — 91KB
- tm2421368d1_ex99-2img012.jpg (GRAPHIC) — 102KB
- tm2421368d1_ex99-2img013.jpg (GRAPHIC) — 91KB
- tm2421368d1_ex99-2img014.jpg (GRAPHIC) — 130KB
- tm2421368d1_ex99-2img015.jpg (GRAPHIC) — 82KB
- tm2421368d1_ex99-2img016.jpg (GRAPHIC) — 156KB
- tm2421368d1_ex99-2img017.jpg (GRAPHIC) — 109KB
- tm2421368d1_ex99-2img018.jpg (GRAPHIC) — 85KB
- tm2421368d1_ex99-2img019.jpg (GRAPHIC) — 180KB
- 0001104659-24-088353.txt ( ) — 3441KB
- tela-20240812.xsd (EX-101.SCH) — 3KB
- tela-20240812_lab.xml (EX-101.LAB) — 33KB
- tela-20240812_pre.xml (EX-101.PRE) — 22KB
- tm2421368d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On August 12, 2024, TELA Bio, Inc. (the " Company ") issued a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of this press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as expressly set forth by specific reference in such filing.
01
Item 7.01 Regulation FD Disclosure. On August 12, 2024, the Company updated information reflected in a corporate slide deck, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.2, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Press Release of TELA Bio, Inc., dated August 12, 2024. 99.2 Corporate Slide Deck, dated August 12, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: President, Chief Executive Officer and Director Date: August 12, 2024